{"protocolSection": {"identificationModule": {"nctId": "NCT01070888", "orgStudyIdInfo": {"id": "08080372"}, "organization": {"fullName": "Boston Children's Hospital", "class": "OTHER"}, "briefTitle": "Trial on the Effect of Budesonide/Formoterol and Inhaled Budesonide Alone on Exercise-Induced Asthma", "officialTitle": "A Randomized, Double-blind, Double Dummy Crossover Trial on the Effect of Budesonide/Formoterol and Inhaled Budesonide Alone on Exercise-Induced Asthma in Patients With Persistent Asthma"}, "statusModule": {"statusVerifiedDate": "2021-07", "overallStatus": "TERMINATED", "whyStopped": "Unable to reach target goal", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-02"}, "primaryCompletionDateStruct": {"date": "2014-04", "type": "ACTUAL"}, "completionDateStruct": {"date": "2014-04", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-02-17", "studyFirstSubmitQcDate": "2010-02-17", "studyFirstPostDateStruct": {"date": "2010-02-18", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2014-11-19", "resultsFirstSubmitQcDate": "2014-12-17", "resultsFirstPostDateStruct": {"date": "2014-12-30", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2021-07-02", "lastUpdatePostDateStruct": {"date": "2021-07-07", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Wanda Phipatanakul", "investigatorTitle": "Study PI", "investigatorAffiliation": "Boston Children's Hospital"}, "leadSponsor": {"name": "Boston Children's Hospital", "class": "OTHER"}, "collaborators": [{"name": "Brigham and Women's Hospital", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The purpose of this study is to find out if Symbicort\u00ae (budesonide/formoterol), a new combination asthma medication, is more effective than budesonide alone in controlling exercise induced asthma.\n\nThe investigators hypothesize that in children and adults who suffer from asthma and exercise induced asthma there will be less decline in lung function associated with exercise when they receive the study medication.", "detailedDescription": "The purpose of this study is to find out if Symbicort\u00ae (budesonide/formoterol), a new combination asthma medication, is more effective than budesonide alone in controlling exercise induced asthma.\n\nThe investigators hypothesize that in children and adults who suffer from asthma and exercise induced asthma there will be less decline in lung function associated with exercise when they receive the study medication.\n\n40 subjects will be randomized to receive both active medications in separate testing periods to determine the effect on their lung function after exercise testing."}, "conditionsModule": {"conditions": ["Exercise Induced Asthma"], "keywords": ["Asthma", "Exercise Induced Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 6, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Budesonide/Formoterol first", "type": "EXPERIMENTAL", "description": "This arm will receive blinded budesonide/formoterol and dummy inhaler and will be asked to take 2 inhalations of each inhaler, twice daily. The second study period will be budesonide and dummy inhaler.", "interventionNames": ["Drug: Budesonide/Formoterol", "Drug: Budesonide"]}, {"label": "Budesonide first", "type": "ACTIVE_COMPARATOR", "description": "This arm will receive blinded budesonide and dummy inhaler and will be asked to take 2 inhalations of each inhaler, twice daily. The second study period will be budesonide/formoterol and dummy inhaler.", "interventionNames": ["Drug: Budesonide/Formoterol", "Drug: Budesonide"]}], "interventions": [{"type": "DRUG", "name": "Budesonide/Formoterol", "description": "Budesonide/Formoterol 160/4.5, 2 puff twice daily for 2 weeks", "armGroupLabels": ["Budesonide first", "Budesonide/Formoterol first"], "otherNames": ["Symbicort"]}, {"type": "DRUG", "name": "Budesonide", "description": "Budesonide 180mcg, 2 puffs twice daily for 2 weeks", "armGroupLabels": ["Budesonide first", "Budesonide/Formoterol first"], "otherNames": ["Pulmicort"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Mean Difference Between Maximal Percentage Decrease in FEV1 After the Exercise Challenge Compared to the Run in Period, Budesonide/Formoterol - Budesonide", "description": "Mean difference between maximal percentage decrease in FEV1 after the exercise challenge compared to the run in period, budesonide/formoterol - budesonide, calculated as follows:\n\n(max fall in FEV1(baseline) - maximal fall in FEV1(bud/form) - (max fall in FEV1(baseline) - maximal fall in FEV1(bud))", "timeFrame": "8 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male or Female Patients aged 12 to 50 years with a diagnosis of asthma for at least 6 months before screening\n* Baseline FEV1 of 60% to \\>100% of predicted\n* Demonstrate a decrease in FEV1 of 15% or greater from baseline after standardized stepped exercise challenge testing\n* Taking a constant dose of low-medium dose inhaled steroids for at least 30 days before screening of either:\n\n  1. fluticasone, 88 - 440 mcg/d via MDI or 100 to 500 mcg/d via DPI\n  2. beclomethasone HFA 80 to 480 mcg/day\n  3. budesonide DPI 180 to 1200 mcg/ d\n  4. flunisolide 500 to 2000 mcg/d\n  5. flunisolide HFA 320 to 640 mcg/d\n  6. mometasone 200 to 800 mcg/d\n  7. triamcinolone acetonide 300 to 1500 mcg/ d\n\nExclusion Criteria:\n\n* Patients already on LABAs, systemic corticosteroids, or other combination inhaled steroids/LABA medications.\n* Patients not able to safely complete an exercise challenge due to physical constraints outside of their respiratory status.\n* Patients who are pregnant or plan to become pregnant during the study period.\n* Patients with a history of hypersensitivity reaction to either formoterol or budesonide.\n* Patients with any significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or influence the results of the study, or the patient's ability to participate in the study.\n* Patients with planned hospitalization during the study\n* Current Smokers or those with a history of 10 pack years of tobacco use or more.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "maximumAge": "50 Years", "stdAges": ["CHILD", "ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Wanda Phipatanakul, MD,MS", "affiliation": "Boston Children's Hospital", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Jonathan M Gaffin, MD", "affiliation": "Boston Children's Hospital", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Brigham and Women's Hospital", "city": "Boston", "state": "Massachusetts", "zip": "02115", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "Children's Hospital Boston", "city": "Boston", "state": "Massachusetts", "zip": "02115", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}]}, "referencesModule": {"references": [{"pmid": "24267370", "type": "DERIVED", "citation": "Gaffin JM, Bouzaher A, McCown M, Larabee Tuttle K, Israel E, Phipatanakul W. Rethinking the prevalence of exercise-induced bronchoconstriction in patients with asthma. Ann Allergy Asthma Immunol. 2013 Dec;111(6):567-8. doi: 10.1016/j.anai.2013.10.005. Epub 2013 Oct 30. No abstract available."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "excluded from failed run-in or not qualify by exercise challenge", "recruitmentDetails": "October 2010 to October 2012", "groups": [{"id": "FG000", "title": "Budesonide First", "description": "This arm will receive blinded budesonide and dummy inhaler and will be asked to take 2 inhalations of each inhaler, twice daily. Subjects will subsequently take blinded budesonide/formoterol and dummy inhale, 2 inhalations of each, twice daily.\n\nBudesonide : Budesonide 180mcg, 2 puffs twice daily for 2 weeks"}, {"id": "FG001", "title": "Budesonide/Formoterol First", "description": "This arm will receive blinded budesonide/formoterol and dummy inhaler and will be asked to take 2 inhalations of each inhaler, twice daily. Subjects will subsequently take blinded budesonide and dummy inhale, 2 inhalations of each, twice daily.\n\nBudesonide/Formoterol : Budesonide/Formoterol 160/4.5, 2 puff twice daily for 2 weeks"}], "periods": [{"title": "First Intervention (14 Days)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}, {"title": "Washout (14 Days)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Second Intervention (14 Days)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Budesonide First", "description": "This arm will receive blinded budesonide and dummy inhaler and will be asked to take 2 inhalations of each inhaler, twice daily.\n\nBudesonide first: Budesonide 180mcg, 2 puffs twice daily for 2 weeks, followed by a washout, then Budesonide/Formoterol 160/4.5, 2 puff twice daily for 2 weeks"}, {"id": "BG001", "title": "Budesonide/Formoterol First", "description": "This arm will receive blinded budesonide/formoterol and dummy inhaler and will be asked to take 2 inhalations of each inhaler, twice daily.\n\nBudesonide/Formoterol : Budesonide/Formoterol 160/4.5, 2 puff twice daily for 2 weeks, followed by a washout, then Budesonide 180mcg, 2 puffs twice daily for 2 weeks,"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "6"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "29.5", "lowerLimit": "18", "upperLimit": "41"}, {"groupId": "BG001", "value": "22.5", "lowerLimit": "15", "upperLimit": "33"}, {"groupId": "BG002", "value": "24.8", "lowerLimit": "15", "upperLimit": "41"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "4"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "2"}]}]}]}, {"title": "FEV1 fall % predicted with exercise", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percent fall in FEV1", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "15.5", "spread": "0.6"}, {"groupId": "BG001", "value": "61.1", "spread": "13.0"}, {"groupId": "BG002", "value": "45.9", "spread": "25.6"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Mean Difference Between Maximal Percentage Decrease in FEV1 After the Exercise Challenge Compared to the Run in Period, Budesonide/Formoterol - Budesonide", "description": "Mean difference between maximal percentage decrease in FEV1 after the exercise challenge compared to the run in period, budesonide/formoterol - budesonide, calculated as follows:\n\n(max fall in FEV1(baseline) - maximal fall in FEV1(bud/form) - (max fall in FEV1(baseline) - maximal fall in FEV1(bud))", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of fall in FEV1", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Budesonide First", "description": "This arm will receive blinded budesonide and dummy inhaler and will be asked to take 2 inhalations of each inhaler, twice daily. Then in the subsequent study period take budesonide/formoterol plus dummy inhaler 2 inhalations of each inhaler, twice daily\n\nBudesonide : Budesonide 180mcg, 2 puffs twice daily for 2 weeks"}, {"id": "OG001", "title": "Budesonide/Formoterol First", "description": "This arm will receive blinded budesonide/formoterol and dummy inhaler and will be asked to take 2 inhalations of each inhaler, twice daily, then in the subsequent period take budesonide and dummy inhaler 2 puffs twice daily.\n\nBudesonide/Formoterol : Budesonide/Formoterol 160/4.5, 2 puff twice daily for 2 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3.1", "spread": "0"}, {"groupId": "OG001", "value": "-19.4", "spread": "30.5"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Throughout entire study, 2 years", "eventGroups": [{"id": "EG000", "title": "Budesonide/Formoterol", "description": "This arm will receive blinded budesonide/formoterol and dummy inhaler and will be asked to take 2 inhalations of each inhaler, twice daily.\n\nBudesonide/Formoterol: Budesonide/Formoterol 160/4.5, 2 puff twice daily for 2 weeks, followed by a washout, then Budesonide 180mcg, 2 puffs twice daily for 2 weeks", "seriousNumAffected": 0, "seriousNumAtRisk": 5, "otherNumAffected": 1, "otherNumAtRisk": 5}, {"id": "EG001", "title": "Budesonide", "description": "This arm will receive blinded budesonide and dummy inhaler and will be asked to take 2 inhalations of each inhaler, twice daily.\n\nBudesonide: Budesonide 180mcg, 2 puffs twice daily for 2 weeks, followed by a washout, then Budesonide/formoterol 180mcg, 2 puffs twice daily for 2 weeks", "seriousNumAffected": 0, "seriousNumAtRisk": 4, "otherNumAffected": 0, "otherNumAtRisk": 4}], "otherEvents": [{"term": "asthma exacerbation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "one subject had an asthma exacerbation requiring ED evaluation during the budesonide formoterol intervention. The subject recovered completely.", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Wanda Phipatanakul", "organization": "Boston Children's Hospital", "email": "wanda.phipatanakul@childrens.harvard.edu", "phone": "857-218-5336"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}, {"id": "D000001250", "term": "Asthma, Exercise-Induced"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}, {"id": "D000092202", "term": "Exercise-Induced Allergies"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M4557", "name": "Asthma, Exercise-Induced", "asFound": "Exercise Induced Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "M2906", "name": "Exercise-Induced Allergies", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000019819", "term": "Budesonide"}, {"id": "D000068759", "term": "Formoterol Fumarate"}, {"id": "D000069502", "term": "Budesonide, Formoterol Fumarate Drug Combination"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000005938", "term": "Glucocorticoids"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M21711", "name": "Budesonide", "asFound": "Of 1", "relevance": "HIGH"}, {"id": "M304", "name": "Formoterol Fumarate", "asFound": "Nicotine", "relevance": "HIGH"}, {"id": "M452", "name": "Budesonide, Formoterol Fumarate Drug Combination", "asFound": "Early Stage", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M9047", "name": "Glucocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}